2015
Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures
Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, Ho PM, Eapen ZJ, Hernandez AF, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM. Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation 2015, 132: 1347-1353. PMID: 26316616, PMCID: PMC4941099, DOI: 10.1161/circulationaha.115.014281.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBody Mass IndexCardiovascular AgentsComorbidityContraindicationsCross-Sectional StudiesDrug HypersensitivityDrug PrescriptionsDrug SubstitutionDrug Therapy, CombinationDrug UtilizationEvidence-Based MedicineFemaleGuideline AdherenceHeart FailureHospitalsHumansMaleMedication AdherenceMiddle AgedPatient AdmissionPatient DischargePolypharmacyPractice Guidelines as TopicQuality Assurance, Health CareConceptsHF quality measuresHydralazine/isosorbide dinitrateAngiotensin receptor blockersMedication groupHeart failureAldosterone antagonistsReceptor blockersMedication regimenIsosorbide dinitrateNew medicationsΒ-blockersEnzyme inhibitorsGuideline-directed medical therapyInitiation of angiotensinPrimary discharge diagnosisQuarter of patientsPatient's medication regimenHospital quality measuresAdequate prescribingMedication initiationHospital dischargeHospital admissionMedical therapyGuideline recommendationsDischarge diagnosis
2014
Caution Warranted When Defining Contraindications in Initiating β-Blocker Therapy—Reply
Dharmarajan K, Krumholz HM. Caution Warranted When Defining Contraindications in Initiating β-Blocker Therapy—Reply. JAMA Internal Medicine 2014, 174: 481-482. PMID: 24590098, DOI: 10.1001/jamainternmed.2013.13685.Peer-Reviewed Original Research
2013
Contraindicated Initiation of β-Blocker Therapy in Patients Hospitalized for Heart Failure
Dharmarajan K, Masoudi FA, Spertus JA, Li SX, Krumholz HM. Contraindicated Initiation of β-Blocker Therapy in Patients Hospitalized for Heart Failure. JAMA Internal Medicine 2013, 173: 1547-1549. PMID: 23797379, PMCID: PMC4043342, DOI: 10.1001/jamainternmed.2013.7717.Peer-Reviewed Original Research
2010
A Perspective on the American Heart Association/American College of Cardiology Science Advisory on Thiazolidinedione Drugs and Cardiovascular Risks
Krumholz HM. A Perspective on the American Heart Association/American College of Cardiology Science Advisory on Thiazolidinedione Drugs and Cardiovascular Risks. Circulation Cardiovascular Quality And Outcomes 2010, 3: 221-222. PMID: 20181986, DOI: 10.1161/circoutcomes.110.936070.Peer-Reviewed Original Research
2006
Influenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology
Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology. Journal Of The American College Of Cardiology 2006, 48: 1498-1502. PMID: 17010820, DOI: 10.1016/j.jacc.2006.09.004.Peer-Reviewed Original ResearchConceptsSecondary preventionCardiovascular diseaseCardiovascular conditionsAmerican CollegeAmerican Heart Association/American CollegeInfluenza vaccination coverage levelsInfluenza vaccination coverage ratesComprehensive secondary preventionAtherosclerotic vascular diseaseVaccination coverage ratesRandomized clinical trialsAmerican Heart AssociationVaccination coverage levelsCardiovascular morbidityCause mortalityInfluenza immunizationInfluenza vaccinationCohort studyInfluenza seasonInfluenza vaccineScience AdvisoryHeart AssociationAnnual vaccinationVascular diseaseClinical trials
2005
Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure
Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure. Circulation 2005, 111: 583-590. PMID: 15699279, DOI: 10.1161/01.cir.0000154542.13412.b1.Peer-Reviewed Original ResearchConceptsHeart failureInsulin-sensitizing drugsOlder patientsLower riskCox proportional hazards modelAntidiabetic drug prescriptionRetrospective cohort studyPrincipal discharge diagnosisClustering of patientsProportional hazards modelCohort studySecondary outcomesPrimary outcomeMetformin treatmentRandomized trialsThiazolidinedione treatmentDischarge diagnosisInsulin sensitizersAdverse outcomesDrug prescriptionsMultivariable modelObservational studyHospital variablesThiazolidinedione classHigh risk
2004
ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary
Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Antman E, Smith S, Alpert J, Anderson J, Faxon D, Fuster V, Gibbons R, Gregoratos G, Halperin J, Hiratzka L, Hunt S, Jacobs A, Ornato J. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. Circulation 2004, 110: 588-636. PMID: 15289388, DOI: 10.1161/01.cir.0000134791.68010.fa.Peer-Reviewed Original ResearchAdultAge FactorsAgedAmerican Heart AssociationAngioplasty, Balloon, CoronaryCardiovascular AgentsCombined Modality TherapyContraindicationsCoronary AngiographyCoronary Artery BypassCoronary Care UnitsDecision TreesDiagnosis, DifferentialEarly DiagnosisElectrocardiographyEmergency Medical ServicesEmergency Service, HospitalFemaleGuideline AdherenceHeart ArrestHeart Conduction SystemHumansMaleMiddle AgedMyocardial InfarctionOutcome Assessment, Health CarePatient DischargePatient Education as TopicPatient SelectionRisk AssessmentRisk FactorsSeverity of Illness IndexSex FactorsSurvival AnalysisThrombolytic TherapyUnited StatesACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)
Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Antman E, Smith S, Alpert J, Anderson J, Faxon D, Fuster V, Gibbons R, Gregoratos G, Halperin J, Hiratzka L, Hunt S, Jacobs A, Ornato J. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Journal Of The American College Of Cardiology 2004, 44: 671-719. PMID: 15358045, DOI: 10.1016/j.jacc.2004.07.002.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryCardiovascular AgentsContraindicationsCoronary AngiographyCoronary Artery BypassCoronary Care UnitsDecision TreesDiagnosis, DifferentialEarly DiagnosisEmergency Medical ServicesEmergency Service, HospitalHeart ArrestHeart Conduction SystemHumansMyocardial InfarctionOutcome Assessment, Health CarePatient DischargePatient Education as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexThrombolytic Therapy
2003
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study
Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. The BMJ 2003, 327: 1322. PMID: 14656840, PMCID: PMC286319, DOI: 10.1136/bmj.327.7427.1322.Peer-Reviewed Original ResearchMetformin and Thiazolidinedione Use in Medicare Patients With Heart Failure
Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure. JAMA 2003, 290: 81-85. PMID: 12837715, DOI: 10.1001/jama.290.1.81.Peer-Reviewed Original ResearchConceptsHeart failureDiabetic patientsConcomitant diabetesThiazolidinedione useMedicare beneficiariesRetrospective medical record abstractionUse of metforminAdvanced heart failureProportion of patientsHeart failure therapyMedical record abstractionAcute care hospitalsMetformin useFailure therapyHospital dischargeCare hospitalRecord abstractionOptimal carePrimary diagnosisAntihyperglycemic drugsMedicare patientsDrug treatmentPatterns of usePatientsPackage inserts
1999
Early beta-blocker therapy for acute myocardial infarction in elderly patients.
Krumholz H, Radford M, Wang Y, Chen J, Marciniak T. Early beta-blocker therapy for acute myocardial infarction in elderly patients. Annals Of Internal Medicine 1999, 131: 648-54. PMID: 10577326, DOI: 10.7326/0003-4819-131-9-199911020-00003.Peer-Reviewed Original ResearchConceptsEarly beta-blocker therapyBeta-blocker therapyAcute myocardial infarctionMyocardial infarctionElderly patientsEarly useHospital mortality ratePatients 65 yearsMedical chart reviewAcute care hospitalsYears of ageHospital mortalityHospital deathChart reviewPatient demographicsCare hospitalClinical factorsTreatment characteristicsEarly treatmentBaseline differencesObservational studyHigh riskMedicare beneficiariesMortality ratePatients
1998
Beta-Blockers after Myocardial Infarction — For Few Patients, or Many?
Radford M, Krumholz H. Beta-Blockers after Myocardial Infarction — For Few Patients, or Many? New England Journal Of Medicine 1998, 339: 551-553. PMID: 9709049, DOI: 10.1056/nejm199808203390809.Peer-Reviewed Original Research
1997
Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age
Krumholz H, Vaccarino V, Ellerbeck E, Kiefe C, Hennen J, Kresowik T, Gold J, Jencks S, Radford M. Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age. The American Journal Of Cardiology 1997, 79: 581-586. PMID: 9068512, DOI: 10.1016/s0002-9149(96)00819-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlabamaAngiotensin-Converting Enzyme InhibitorsConnecticutContraindicationsControlled Clinical Trials as TopicDecision MakingDiabetes ComplicationsDiureticsDrug PrescriptionsDrug UtilizationFemaleFollow-Up StudiesHeart FailureHospitalizationHumansIowaMaleMedicaidMultivariate AnalysisMyocardial InfarctionPatient DischargeRetrospective StudiesStroke VolumeTachycardia, VentricularUnited StatesVentricular Function, LeftWisconsinConceptsAcute myocardial infarctionACE inhibitorsMyocardial infarctionDischarge medicationsVentricular functionEnzyme inhibitorsLeft ventricular ejection fractionAngiotensin-converting enzyme inhibitorAngiotensin converting enzyme (ACE) inhibitorsVentricular Enlargement (SAVE) trialCongestive heart failureVentricular ejection fractionYears of ageEligible patientsPatient characteristicsAppropriate patientsDiabetes mellitusEjection fractionHeart failureLoop diureticsMultivariable analysisVentricular tachycardiaIdeal patientObservational studyPatients
1996
Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes.
Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Jencks SF. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Annals Of Internal Medicine 1996, 124: 292-8. PMID: 8554223, DOI: 10.7326/0003-4819-124-3-199602010-00002.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrescription of aspirinMyocardial infarctionPatient characteristicsPrescribed useMortality rate 6 monthsBetter overall health statusRate 6 monthsBeta-blocker therapyPatients 65 yearsUse of aspirinPatient demographic characteristicsAcute care hospitalsOverall health statusPrescribed aspirinDischarge medicationsElderly patientsHospital dischargeSecondary preventionCare hospitalClinical factorsMedical chartsMultivariable analysisCardiac proceduresTreatment characteristics
1993
Coronary revascularization after myocardial infarction in the very elderly: outcomes and long-term follow-up.
Krumholz HM, Forman DE, Kuntz RE, Baim DS, Wei JY. Coronary revascularization after myocardial infarction in the very elderly: outcomes and long-term follow-up. Annals Of Internal Medicine 1993, 119: 1084-90. PMID: 8239227, DOI: 10.7326/0003-4819-119-11-199312010-00005.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCardiac CatheterizationContraindicationsFemaleFollow-Up StudiesHemodynamicsHospital MortalityHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationProportional Hazards ModelsQuality of LifeRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsAcute myocardial infarctionCoronary revascularizationMyocardial infarctionElderly patientsComplicated acute myocardial infarctionConsecutive patients 80 yearsCoronary artery bypass surgeryTertiary care teaching hospitalCox proportional hazards modelMedical therapy groupPatients 80 yearsRetrospective cohort studyArtery bypass surgerySevere valvular diseaseSignificant coronary diseaseInvasive cardiovascular proceduresProportional hazards modelQuality of lifeAngioplasty groupSurgery groupBypass surgeryCohort studyCardiac catheterizationCoronary diseaseSerious complications